top of page

UCB acquired Ra Pharmaceuticals, the company hoping high from myasthenia gravis product

UCB has announced that it has acquired Ra Pharmaceuticals, a clinical-stage biopharmaceutical company.

Ra Pharmaceuticals lead product is zilucoplan, which is indifferent phases for different indications.

Different phases and the indications of the product are

  • Phase III: Myasthenia gravis

  • Phase II: Immune-mediated necrotizing myopathy; Paroxysmal nocturnal hemoglobinuria

  • Phase I: Haemolytic uraemic syndrome; Lupus nephritis

UCB believes that along with rozanolixizumab, UCB’s FcRn targeting antibody, the company is hoping to play a vital role in the space of myasthenia gravis.

Ra Pharmaceuticals is a US-based company with a research and development unit in Cambridge, MA. UCB is also expecting it to have better access to the Boston area with this acquisition.

The transaction is worth $2.3 billion, and UCB is paying 48 in cash per Ra Pharma share.

“In the last 15 months, we made several significant steps on UCB’s strategic growth path, namely the “Accelerate and Expand” phase. This acquisition is a key part of this progress and an excellent strategic fit with UCB’s strategy,” said Jean-Christophe Tellier, CEO UCB.

The company is expecting the acquisition to help from 2024.


Recent Posts

See All

Australia Healthcare News | Media | Updates

New medications, Jemperli and Korsuva will be available for endometrial cancer and chronic kidney disease For women facing advanced or recurring endometrial cancer, a medication called Jemperli (dosta


bottom of page